Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712187 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of ALTO-100 in MDD
A Phase 2 study of Major Depressive Disorder, sponsored by Alto Neuroscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 301
- Enrollment target
- 20
- Study locations
NCT05712187 is a Phase 2 study of Major Depressive Disorder that has completed, run by Alto Neuroscience. The registered enrollment target is 301 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT05712187, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by Alto Neuroscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 301 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALTO-100
Study Locations (20)
California
- Site 141 - Costa Mesa
- Site 118 - Fresno
- Site 181 - Imperial
- Site 182 - Oceanside
- Site 188 - Oceanside
- Site 179 - Rancho Cucamonga
- Site 116 - Sacramento
Florida
- Site 186 - Brooksville
- Site 204 - Jacksonville
- Site 205 - Orlando
- Site 212 - Tampa
- Site 213 - Tampa
Alabama
- Site 174 - Birmingham
- Site 173 - Huntsville
Arizona
- Site 136 - Chandler
Arkansas
- Site 139 - Little Rock
Colorado
- Site 185 - Centennial
Indiana
- Site 137 - Carmel
Maryland
- Site 151 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2023-01-10 |
| Est. Completion | 2024-10-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05712187
The ClinicalTrials.gov registry entry for NCT05712187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 301 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (20% lower). The listed sponsor is Alto Neuroscience, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05712187 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05712187 about?
NCT05712187 is a clinical study titled "Phase 2b Study of ALTO-100 in MDD". The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidepressant, related to patient characteristics.
What is the current status of trial NCT05712187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 301 participants. The study started on 2023-01-10. Estimated completion is 2024-10-24.
What conditions does trial NCT05712187 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05712187?
The interventions under investigation include: Placebo (DRUG), ALTO-100 (DRUG).
Who is sponsoring clinical trial NCT05712187?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05712187 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.